^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PCSK9 inhibitor

    Related drugs:
    25d
    Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose. (clinicaltrials.gov)
    P1, N=400, Recruiting, Amgen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Repatha (evolocumab)
    30d
    A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects (clinicaltrials.gov)
    P1, N=230, Completed, Akeso | Not yet recruiting --> Completed
    Trial completion
    30d
    ONTOP: Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial (clinicaltrials.gov)
    P2, N=32, Recruiting, Shanghai Pudong Hospital | Not yet recruiting --> Recruiting | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Jul 2026 --> Jul 2027
    Enrollment open • Trial completion date • Trial primary completion date • pMMR
    |
    Avastin (bevacizumab) • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • oxaliplatin • irinotecan • leucovorin calcium • Junshida (ongericimab)
    1m
    A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) (clinicaltrials.gov)
    P3, N=975, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    APOB (Apolipoprotein B)
    1m
    STAR-SCLC: Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • Tyvyt (sintilimab) • etoposide IV
    1m
    Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose (clinicaltrials.gov)
    P1, N=405, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Repatha (evolocumab)
    1m
    A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia (clinicaltrials.gov)
    P2, N=120, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults (clinicaltrials.gov)
    P1, N=44, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    1m
    A Phase I, Cross-over Study Comparing the Relative Bioavailability of Laroprovstat Plus Ezetimibe Fixed Combination Drug Products Versus Their Single Therapy Products in Healthy Adults (clinicaltrials.gov)
    P1, N=18, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors (clinicaltrials.gov)
    P2/3, N=126, Recruiting, Beijing Suncadia Pharmaceuticals Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    APOB (Apolipoprotein B)
    1m
    Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD) (clinicaltrials.gov)
    P=N/A, N=4545, Completed, Sanofi | Active, not recruiting --> Completed
    Trial completion
    |
    Praluent (alirocumab)
    2ms
    CKJX839A12309: Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes (2025-521670-34-00)
    P2/3, N=135, Recruiting, Novartis Pharma AG
    New P2/3 trial
    |
    atorvastatin